Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells
In vitro comparisons of induction of perforin (PFP), granzyme B (GRB), production of cytokines, and cell-mediated cytotoxicity by interleukin-2 (IL-2), interleukin-15 (IL-15), or combinational IL-2/IL-15-induced lymphokine-activated killer cells were studied in this study. Whereas IL-2-induction was...
Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 115(2005), 3 vom: 31. Juni, Seite 240-9 |
---|---|
1. Verfasser: | |
Weitere Verfasser: | |
Format: | Aufsatz |
Sprache: | English |
Veröffentlicht: |
2005
|
Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
Schlagworte: | Journal Article Research Support, Non-U.S. Gov't Interleukin-15 Interleukin-2 Lymphokines Membrane Glycoproteins Pore Forming Cytotoxic Proteins Tumor Necrosis Factor-alpha Perforin 126465-35-8 mehr... |
Zusammenfassung: | In vitro comparisons of induction of perforin (PFP), granzyme B (GRB), production of cytokines, and cell-mediated cytotoxicity by interleukin-2 (IL-2), interleukin-15 (IL-15), or combinational IL-2/IL-15-induced lymphokine-activated killer cells were studied in this study. Whereas IL-2-induction was associated with a decrease in cultured cell population over a 7-day period, IL-15 alone or in combination with IL-2 resulted in significant increase including cytotoxic T lymphocytes and subsets of CD56+ lymphocytes, particularly cytokine-induced killer and cytolytic natural killer-T lymphocytes. The overall PFP, GRB, and tumor necrosis factor-alpha expression in different subtypes were also significantly higher with IL-15 alone or in combination with IL-2 induction with resultant superior cytotoxicity compared to IL-2 treatment. There was no significant advantage of addition of IL-2 over IL-15 induction. These results offer further information on the cytotoxic potency of these cytokines and their mechanisms of action implicating potential use of IL-15 as part of cytokine adoptive immunotherapy |
---|---|
Beschreibung: | Date Completed 14.07.2005 Date Revised 21.11.2008 published: Print Citation Status MEDLINE |
ISSN: | 1521-7035 |